ACS chemical neuroscience molecule spotlight on Lorcaserin.
Lorcaserin (APD-356) is the first in a new class of selective serotonin 5-hydroxytryptamine(2C) (5-HT(2C)) receptor agonists. On December 22, 2009, the compound's developer (Arena Pharmaceuticals) submitted an NDA to the FDA for approval for weight management.
Department of Pharmacology and Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee 37232-6600, USA.
Corey R
CR
Hopkins
D019440:Anti-Obesity Agents / Q000737:chemistry / Q000494:pharmacology*; D001552:Benzazepines / Q000737:chemistry / Q000494:pharmacology*; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D009765:Obesity / Q000188:drug therapy; D044405:Receptor, Serotonin, 5-HT2C / Q000187:drug effects*; D058826:Serotonin 5-HT2 Receptor Agonists / Q000737:chemistry / Q000494:pharmacology*; D014481:United States; D014486:United States Food and Drug Administration
D019440:Anti-Obesity Agents; D001552:Benzazepines; D044405:Receptor, Serotonin, 5-HT2C; D058826:Serotonin 5-HT2 Receptor Agonists; C506658:lorcaserin